## **Resource Summary Report**

Generated by dkNET on Apr 29, 2025

# **Yoda Project**

RRID:SCR\_022761

Type: Tool

### **Proper Citation**

Yoda Project (RRID:SCR\_022761)

#### **Resource Information**

URL: https://yoda.yale.edu/

**Proper Citation:** Yoda Project (RRID:SCR\_022761)

**Description:** Project to promote and facilitate sharing of clinical trial data. Provides set of policies to set standards to enhance data availability and transparency in support of strong scientific research which aims to advance scientific and medical knowledge with goal of improving public health and healthcare delivery. Project has the final decision making rights regarding these policies and granting or denial of data requests, as per contractual agreements between the YODA Project and its partners.

**Synonyms:** Yale university Open Data Access project, YODA Project, Yale University Open Data Access Project

Resource Type: data or information resource, project portal, portal

**Keywords:** Data sharing project for clinical trials, clinical trial data, policies, standards to enhance data availability and transparency, granting or denial of data requests

#### **Funding:**

Availability: Free, Freely available

Resource Name: Yoda Project

Resource ID: SCR\_022761

**Record Creation Time:** 20220920T050146+0000

Record Last Update: 20250429T060212+0000

## **Ratings and Alerts**

No rating or validation information has been found for Yoda Project.

No alerts have been found for Yoda Project.

#### Data and Source Information

Source: SciCrunch Registry

## **Usage and Citation Metrics**

We found 121 mentions in open access literature.

**Listed below are recent publications.** The full list is available at dkNET.

Tica J, et al. (2025) Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial. Human vaccines & immunotherapeutics, 21(1), 2450120.

Badros A, et al. (2025) Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. Blood, 145(3), 300.

Cai Z, et al. (2025) Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC-1. Cancer, 131(1), e35665.

Tapia-Calle G, et al. (2025) Safety, reactogenicity, and immunogenicity of Ad26.COV2.S coadministered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trial. EClinicalMedicine, 79, 103016.

Calvo E, et al. (2025) A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer. The oncologist, 30(1).

Blum M, et al. (2025) Epidemiology of invasive Escherichia coli disease in adults in England, 2013-2017. Epidemiology and infection, 153, e4.

Ishida T, et al. (2025) A Phase 1/2 study of teclistamab, a humanized BCMA?x?CD3 bispecific Ab in Japanese patients with relapsed/refractory MM. International journal of hematology, 121(2), 222.

Almansour SA, et al. (2024) Association of proton pump inhibitor use with survival and adverse effects outcomes in patients with multiple myeloma: pooled analysis of three clinical trials. Scientific reports, 14(1), 591.

Macle L, et al. (2024) Safety and acute performance of atrial fibrillation ablation using a temperature-controlled, very high-power short-duration catheter and a new radiofrequency

generator. Journal of interventional cardiac electrophysiology: an international journal of arrhythmias and pacing, 67(3), 453.

Ferrannini E, et al. (2024) Role of Glycosuria in SGLT2 Inhibitor-Induced Cardiorenal Protection: A Mechanistic Analysis of the CREDENCE Trial. Diabetes, 73(2), 250.

Efstathiou E, et al. (2024) Perception of cure in prostate cancer: human-led and artificial intelligence-assisted landscape review and linguistic analysis of literature, social media and policy documents. ESMO open, 9(5), 103007.

Julg B, et al. (2024) Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy. NPJ vaccines, 9(1), 89.

Hosman T, et al. (2024) Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life. Human vaccines & immunotherapeutics, 20(1), 2344970.

Turkoz I, et al. (2024) Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations. The international journal of neuropsychopharmacology, 27(2).

Almansour SA, et al. (2024) Antithrombotic utilization, adverse events, and associations with treatment outcomes in multiple myeloma: pooled analysis of three clinical trials. Therapeutic advances in medical oncology, 16, 17588359241275387.

Jastorff A, et al. (2024) Immunogenicity, safety and reactogenicity of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 to 75 years: A comparison of phase 2b and phase 3 clinical trial material. Human vaccines & immunotherapeutics, 20(1), 2383504.

Carpp LN, et al. (2024) Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial. Nature communications, 15(1), 9785.

Afif W, et al. (2024) Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study. The American journal of gastroenterology, 119(5), 910.

Simpson EL, et al. (2024) Interleukin-1? inhibitor bermekimab in patients with atopic dermatitis: randomized and nonrandomized studies. Archives of dermatological research, 316(8), 589.

Nelson GW, et al. (2024) Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine regimen by HLA class I alleles. Journal of virology, 98(8), e0028124.